By Ludwig Burger (Reuters) - Sanofi (NASDAQ:)'s most superior a number of sclerosis (MS) drug candidate has missed the principle aim of two late-stage trials to deal with relapsing types...
By Maggie FickLONDON (Reuters) -Novo Nordisk on Wednesday trimmed its full-year income outlook after reporting weaker-than-expected quarterly product sales of its widespread weight-loss drug Wegovy, stirring worries amongst patrons about stiffening rivals from...
Shares of Invivyd (NASDAQ:IVVD) closed 42% increased Friday after the biotech firm introduced it had obtained FDA emergency use authorization, or EUA, for its COVID-19 prophylactic drug Pemgarda and launched Part...
Whereas Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) will seemingly rule the weight problems drug marketplace for the following decade, rivals equivalent to Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) might quickly be...
